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Abstract
Background: Reversible cerebral vasoconstriction syndrome (RCVS) could be complicated by cerebral ischemic events.
Hypothetical mechanisms of RCVS involve endothelial dysfunction and sympathetic overactivity, both of which were
reported to be related to brain-derived neurotrophic factor (BDNF). The study investigated the association between
functional BDNF Val66Met polymorphism and RCVS.
Methods: Patients with RCVS and controls were prospectively recruited and genotyped for the BDNF Val66Met
polymorphism. Magnetic resonance angiography (MRA) and transcranial color-coded Doppler sonography were employed
to evaluate cerebral vasoconstriction. Genotyping results, clinical parameters, vasoconstriction scores, mean flow velocities
of the middle cerebral artery (VMCA), and Lindegaard indices were analyzed. Split-sample approach was employed to
internally validate the data.
Principal Findings: Ninety Taiwanese patients with RCVS and 180 age- and gender-matched normal controls of the same
ethnicity completed the study. The genotype frequencies did not differ between patients and controls. Compared to
patients with Met/Met homozygosity, patients with Val allele had higher mean vasoconstriction scores of all arterial
segments (1.6060.72 vs. 0.8760.39, p,0.001), VMCA values (116.7636.2 vs. 82.7617.9 cm/s, p,0.001), and LI (2.4160.91 vs.
1.8960.41, p=0.001). None of the Met/Met homozygotes, but 38.9% of the Val carriers, had VMCA values of .120 cm/s
(p,0.001). Split-sample validation by randomization, age, entry time or residence of patients demonstrated concordant
findings.
Conclusions: Our findings link BDNF Val66Met polymorphism with the severity of RCVS for the first time and implicate
possible pathogenic mechanisms for vasoconstriction in RCVS.
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Introduction
Reversible cerebral vasoconstriction syndrome (RCVS) is
characterized by recurrent severe headaches, mostly thunderclap
headaches, and reversible cerebral vasoconstriction [1–3]. Cere-
bral vasoconstriction in RCVS is pervasive, outlasts headache
resolution [4], and is the most important component of RCVS.
Severe vasoconstrictions, especially in the M1 segment of the
middle cerebral artery (MCA) and P2 segment of the posterior
cerebral artery (PCA), are associated with higher risks of posterior
reversible encephalopathy syndrome (PRES) and ischemic stroke
[4,5]. In addition, a substantial proportion of patients are
complicated by hemorrhagic complications such as intracerebral
hemorrhage (ICH) or cortical subarachnoid hemorrhage [2,6].
The pathogenesis of RCVS remains enigmatic, although sympa-
thetic over-activity and endothelial dysfunction are proposed to
play important roles. The homogeneity of patient demographic
and clinical characteristics suggests a common diathesis; however,
the possibility of a genetic predisposition for this disease has never
been explored.
Brain-derived neurotrophic factor (BDNF) is important in
neuronal survival, neurogenesis, and synaptic plasticity. Like other
neurotrophins, BDNF utilizes a dual receptor system to modulate
diverse and sometimes opposing biological actions that consists of
a specific high affinity receptor [Neurotrophic tyrosine kinase,
receptor, type 2 (NTKR2), also known as TrkB (a member of the
Trk family of tyrosine kinase receptors)] and a common low
affinity receptor [p75 neurotrophin receptor (p75
NTR)][7–9]. In
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on vascular function, promoting angiogenesis through the TrkB
receptor expressed on endothelial cells [10] and having possible
dual effects on vascular smooth muscle cells through the p75
NTR
receptor [11]. Besides, BDNF has complex interactions with
sympathetic neurons[12,13] and has been implicated in disorders
of vascular tone dysregulation [14].
The human BDNF gene has been mapped to chromosome 11.
A common single nucleotide polymorphism (SNP) (G196A or
Val66Met, dbSNP: rs6265) in the BDNF gene leading to a valine
(Val) to methionine (Met) substitution in codon 66 of the
prodomain, has been shown to impact intracellular trafficking
and activity-dependent secretion of BDNF [15]. This functional
polymorphism was recently found to be associated with unstable
angina, supporting a genetic basis for the BDNF-vascular
interaction [16]. In this study, we hypothesized that the BDNF




Consecutive patients with RCVS were recruited from the
headache clinic at Taipei Veterans General Hospital (TVGH)
between 2005 and 2010. TVGH is a 2,909-bed national medical
center that serves both veterans and non-veteran citizens. This
hospital is located in Taipei City, which is both the capital and a
major urban center in Taiwan, and had a population of
approximately 2,610,000 in 2009. The headache clinic of TVGH
has been operating since 1997. The diagnosis of RCVS was based
on the criteria of its eponymous syndrome ‘‘benign (or reversible)
angiography of the central nervous system’’ proposed by the
International Classification of Headache Disorders, second edition
(ICHD-2) (Code 6.7.3), except for the duration criterion D [17].
The duration criterion was not followed because some patients
took .2 months to recover [3]. Controls were recruited from
neurologic and psychiatric clinics as well as from the medical and
paramedical staffs of TVGH for comparison.
Neuroimaging studies
Protocols of magnetic resonance (MR) studies and transcranial
color-coded sonography (TCCS) have been detailed elsewhere
[4,5]. Briefly, magnetic resonance angiography (MRA) was
obtained using a 3D time-of-flight (TOF) MR technique with
multi-slab reconstruction and maximum intensity projection (MIP)
postprocessing to assess the extent and reversibility of vasoconstric-
tion.Thebasilarartery(BA)andthe firstand second segmentsofthe
anterior cerebral artery (ACA, A1 and A2), MCA (M1 and M2),
and PCA (P1 and P2) were evaluated. Vasoconstriction severity was
graded on a five-point scale, 0 (,10%), 1 (10-,25%), 2 (25-,50%),
3 (50-,75%), and 4 ($ 75%), and designated as the ‘‘vasoconstric-
tion score’’ of each arterial segment. Only patients with multifocal
cerebral vasoconstrictions on the initial MRA and demonstration of
the reversibility of vasoconstrictions on a follow-up MRA were
eligible. The mean flow velocity of the MCA (VMCA) and the
Lindegaard index (LI), which was calculated by dividing the VMCA
by the mean flow velocity of the ipsilateral distal extracranial
internal carotid artery (ICA), were obtained to evaluate the
hemodynamic derangement caused by vasoconstriction.
BDNF polymorphism
Genomic DNA was extracted from EDTA-containing venous
blood samples for BDNF Val66Met polymorphism genotyping
[18]. The DNA fragments of interest were amplified using
polymerase chain reaction (PCR) with the primers 59-ACTCTG-
GAGAGCGTGAAT-39 and 59-ATACTGTCACACACGCTC-
39. The PCR was performed in a total volume of 10 ml containing
50 ng of template DNA, 50 mM KCl, 10 mM Tris–HCl (pH 8.3),
1.5 mM MgCl2, 200 mM of dNTP, 10 pmol of each oligonucle-
otide, and 0.25 U of Taq DNA polymerase. Amplification
conditions consisted of an initial 4-min denaturation step at
94uC, 32 cycles of 30 s at 94uC, 30 s at 58uC, and 30 s at 72uC,
followed by a final extension of 10 min at 74uC. The Val66Met
polymorphism was differentiated with the NlaIII restriction
enzyme. Partial digestion was minimized by an internal restriction
site and a control sample of digestible homozygous Val/Val. The
genotyping was processed blinded to clinical data.
Ethics
The study protocol was approved by the TVGH Institutional
Review Board. All participants provided written informed consent
before entering the study. All clinical investigation was conducted
according to the principles expressed in the Declaration of
Helsinki. The corresponding author had full access to all the data
in the study and had final responsibility for the decision to submit
for publication.
Statistics
In this study, descriptive statistics are presented as the median,
mean 6 SD, or percentages. Means were compared using the
unpaired t-tests, and proportions were compared using the Chi-
square or Fisher’s exact test as appropriate. Genotypes and allele
frequency of patients were analyzed and compared with those
found in controls. The severity of vasoconstriction (mean
vasoconstriction scores, VMCA, and LI) [4,5] was compared
between different genotypes in patients with RCVS by analysis of
variance (ANOVA) test and post-hoc analysis with Scheffe test. To
minimize the risk of false-positive findings, we used a split-sample
approach to internally validate the data [19]. The dataset of
patients with RCVS was split into two approximately equal subsets
by 1:1 randomization or parameters including median age,
median entry time and residence (Taipei City or outside Taipei
City) of the patients. All calculated p-values were two-tailed, and
statistical significance was defined as a p-value of ,0.01 to adjust
type I error resulted from multiple comparisons.
Results
Participants and their characteristics
We recruited 90 Taiwanese RCVS patients and 180 age-and
sex- matched controls (mean age: 48.1610.4 vs. 48.2617.2 year,
p=0.94; Gender ratio: M/F 11/79 vs. 22/158, p=1.00) with the
same ethnicity. The median age of patients was 51. Seventeen
patients (18.9%) had a history of hypertension and 39 (43.3%) had
blood pressure surges during headache attacks. Five patients
(5.6%) had type 2 diabetes mellitus, 18 (20.0%) had migraine, and
none had coronary artery disease. Forty (50.6%) women were
postmenopausal, and eleven (13.9%) were under hormone therapy
at disease onset. Four patients had some possibly associated
conditions, including the use of selective serotonin reuptake
inhibitors, ingestion of pseudoephedrine, left distal vertebral artery
dissection, or microangiopathic hemolytic anemia. Patients had an
average of 6.666.0 (range 2–30) thunderclap headache attacks in
a mean period of 16.868.4 d (range 2–42 d). Triggers were
identifiable in 71 (78.8%) patients. Five patients (5.6%) developed
PRES and five (5.6%) developed ischemic stroke; two had both
PRES and ischemic stroke. One patient with both PRES and
ischemic stroke was also complicated with ICH.
BDNF Val66Met Polymorphism Modulates RCVS
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controls
Comparison of the genotypes and allelic frequencies of the
BDNF Val66Met polymorphism between patients and controls is
presented in Table 1. The distribution of the BDNF Val66Met
genotypes was in Hardy–Weinberg equilibrium in patients and
controls. Neither genotypes nor allele frequencies were different
between patient and control groups.
Genotyping results versus clinical variables in patients
with RCVS
The comparisons of vasoconstriction scores, VMCA and LI
between patients with different genotypes are listed in table 2.
Patients with Val/Val or Val/Met genotypes had more severe
vasoconstrictions than Met/Met carriers, but the severity did not
differ between those with Val/Val and Val/Met genotype
(Table 2). Post-hoc analysis using the dominant model of
inheritance for Val allele disclosed that Val carriers had
significantly higher mean vasoconstriction scores of M1, M2, A1,
and P2, higher VMCA values, and LI than Met/Met homozygotes
(p,0.001 for M1, A1 and VMCA; p=0.001 for M2, P2 and LI). In
addition, we found that none of the Met/Met homozygotes had a
VMCA value .120 cm/s, compared to 38.9% of Val carriers
(p ,0.001). Clinical features and complication risk were not
associated with the polymorphism (Table 2).
Split-sample internal validation
When the dataset was randomly split in half, we found that Val
carriers (Val/Val or Val/Met genotypes) had higher vasoconstric-
tion scores than Met/Met homozygotes in both subgroups (Table
S1). The demographics and genotyping frequencies did not differ
between these two subgroups (complete data not shown). When we
divided the sample by median age, median entry time and
residence as defined, we discovered concordant findings among
these divided subsets (Tables S1, S2, S3, S4).
Discussion
Although the disease profile of RCVS has been delineated, the
underlying mechanisms are largely unknown. Our results showed
that the Val allele in codon 66 of the BDNF gene was associated
with more severe vasoconstriction in patients with RCVS, or on
the contrary, the presence of Met homozygosity had a protective
role. This is the first study to unravel possible genetic substrate of
this highly homogeneous clinical-radiological syndrome. Though there is still a long way to go, this novel finding provides a key to
unlock the pathogenetic networks of this potentially fatal disease.
Because RCVS is not a common disease, accounting for less
than 1% of patients in our headache clinic [3], the case number of
this five-year study has been the largest ever since. To validate our
findings by repeating the same results in another sample with a
similar size is difficult. Thus, our study employed a split-sample
approach for internal validation. Of note, splitting one well-
powered study frequently results in two less conclusive ones [20].
However, even with this trade-off, we obtained similar findings in
different split subsets. Therefore, the genetic association of BDNF
Val66Met is unlikely a false-positive finding.
A previous study investigating the relationship between unstable
angina and the BDNF Val66Met polymorphism similarly identified a
protective effect of the Met/Met genotype [16]. Though the
pathogeneses of RCVS and unstable angina might differ, the
common findings of both studies suggest the benefit of further BDNF
studies in vascular disorders. Because the allelic frequency was similar
between our patients and controls, BDNF Val66Met polymorphism
Table 1. Comparison of genotypes and allelic frequencies for
the brain-derived neurotrophic factor Val66Met
polymorphism between patients with reversible cerebral
vasoconstriction syndrome and controls.




Val/Val Val/Met Met/Met Val Met
Patients
(n=90)
19 (21.1) 45 (50.0) 26 (28.9) 0.87 46.1 53.9 1.00
Controls
(n=180)
35 (19.4) 96 (53.3) 49 (27.2) 46.1 53.9
doi:10.1371/journal.pone.0018024.t001
Table 2. Comparisons of demographics, past medical history,
clinical manifestation and vasoconstriction severity of
reversible cerebral vasoconstriction syndromes in association







(n = 26) P{
Age (y), mean
6 SD
48.9611.0 48.069.5 47.7611.7 0.924
Gender, M/F 4/15 3/42 4/22 0.238
Hypertension, n (%) 2 (10.5) 8 (17.8) 7 (26.9) 0.376
Type 2 DM, n (%) 1 (5.3) 2 (4.4) 1(7.7) 0.850
Migraine, n (%) 3 (15.8) 10 (22.2) 5 (19.2) 0.840
BP surge, n (%) 7 (36.8) 22 (48.9) 10 (38.4) 0.574
Total TCH attacks,
mean 6 SD
9.9610.9 6.264.2 5.263.4 0.097
TCH duration (d),
mean 6 SD
17.5610.3 16.6611.1 16.7613.4 0.970
Mean vasoconstriction score, mean 6 SD
M1 1.2461.02* 1.7861.03* 0.5860.52 ,0.001
M2 1.5361.42 2.1761.04** 1.1260.90 0.001
A1 2.0061.13** 1.9560.97** 0.9060.60 ,0.001
A2 1.3460.97 1.4760.91 0.9660.69 0.064
P1 1.3960.95 1.3761.04 0.8360.78 0.057
P2 2.0361.09* 1.9260.92* 1.1960.98 0.005
BA 0.6360.90 0.7060.93 0.3160.62 0.160
All segments 1.4360.73* 1.7060.70* 0.8760.39 ,0.001
VMCA 111.1633.3* 113.4638.0** 82.7617.9 0.003
LI 2.3260.79 2.4560.97 1.8960.41 0.050
PRES, n (%) 0 (0) 4 (9) 1 (4) 0.338
Ischemic stroke,
n( % )
0 (0) 3 (7) 2 (8) 0.493
BA: basilar artery, BP: blood pressure, DM: diabetes mellitus, LI: Lindegaard
index, PRES: posterior reversible encephalopathy syndrome, TCH: thunderclap
headache, VMCA: mean flow velocity of the middle cerebral artery.
{Derived by analysis of variance (ANOVA) test.
*p,0.05 & **p,0.01 in comparison with Met/Met homozygotes using post-hoc
Scheffe test.
doi:10.1371/journal.pone.0018024.t002
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RCVS. It should be noted that if the BDNF-gene Val66Met
polymorphism is an uncommon disease locus or one with a small
effect, the failure to demonstrate a significant association may reflect
false negative results due to a small sample size. It is also possible that
another BDNF genetic variant is involved in susceptibility to RCVS,
and that the linkage disequilibrium between this genetic variant and
the Val66Met polymorphism did not occur in our study population.
The allele frequencies of the BDNF Val66Met polymorphism
differ among different ethnic populations. The frequency of Met66
allele varies from 0 to 72% among 58 global populations; it is
considerably low in African or Caucasian populations but higher
in Asian descents [21]. This might implicate that patients in
western countries are more vulnerable to severe vasoconstrictions,
and therefore, more complications than Asian patients. However,
whether the results of our study could be generalizable to other
ethnic populations deserve further investigation. Since all cases
and controls in this study were of the same ethnicity and our
observed allele frequencies are consistent with those observed for
Han Chinese, population stratification is unlikely to play a major
confounding role in our study. Nonetheless, the difference in
polymorphism frequency could be a major issue for subsequent
replication studies with different ethnic backgrounds.
The findings of this study raise the significance of potential
biologic actions of BDNF polymorphism on cerebral vasoconstric-
tion. If the findings could be validated with consistent and
independent replication, we might be able to identify patients at a
higher risk of severe vasoconstrictions in the era of personalized
medicine. The mechanisms underlying our findings are not known.
The followings are some possible explanations. First, earlier study
demonstrated that depolarization-induced secretion was reduced in
66Met BDNF-transfected neurons compared with 66Val BDNF
analogs [15]. Thus subjects carrying Val allele may have higher
intracranial BDNF activity than Met/Met homozygotes. Second, it
has been reported that under circumstances of sympathetic
overactivity, BDNF could lead to perivascular inflammation and
thus cause marked vasoconstriction [14]. BDNF has been shown to
dramatically upregulate neuropeptide Y [22], a vasoconstrictive
sympathetic co-transmitter [23]. Since sympathetic overactivity
may play an important role in the pathogenesis of RCVS [24], it is
plausible that subjects with higher intracranial BDNF activity, i.e.,
the Val carriers, could have more severe vasoconstriction. Third,
BDNF-overexpression was found to modulate vascular tone of small
pulmonary arteries through interactions with neurokinin A [25].
Because receptor subtypes of neurokinin A differ between cerebral
and pulmonary arteries, whether the study results could be
extrapolated to RCVS requires further studies.
Limitations
Our study had several limitations. First, the case number in this
study was not large for a genetic polymorphism study and might
have led to false negative results of clinical correlates, such as
thunderclap attacks or total duration. However, the positive results
with large effect sizes alleviated potential type II errors caused by
small sample size. Second, all the patients with VMCA .120 cm/s
were Val carriers. Based on our previous study [5], the risks of
PRES or ischemic stroke in these patients should be higher.
However, because of limited case number with complications in the
present studycohort,we failedto observe this expected finding. One
reason for lower percentage of patients with complications could be
our improving ability of early recognition and treatment for RCVS.
Third, we did not check plasma BDNF levels in patients, and were
unable to ensure whether the modulatory effect of this polymor-
phism came from an altered BDNF level and/or its downstream
pathways. Nonetheless, recent studies demonstrated that plasma
concentration of BDNF was not associated with the Val66Met
variant [26] and there was no significant correlation between serum
and regional brain BDNF levels [27]. Furthermore, the possibility
that theactualcausalSNPwas not theVal66Metpolymorphism per
se but located at a highly linked locus could not be completely
excluded. Large-scaled studies with haplotype analysis or direct
sequencing might be required to answer the question in the future.
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